BDX logo

BDX

Becton Dickinson and Company

$192.69
+$3.11(+1.64%)
62
Overall
70
Value
54
Tech
--
Quality
Market Cap
$53.26B
Volume
1.76M
52W Range
$162.29 - $251.99
Target Price
$210.46

Company Overview

Mkt Cap$53.26BPrice$192.69
Volume1.76MChange+1.64%
P/E Ratio31.2Open$189.92
Revenue$20.2BPrev Close$189.58
Net Income$1.7B52W Range$162.29 - $251.99
Div Yield4.20%Target$210.46
Overall62Value70
Quality--Technical54

No chart data available

About Becton Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Sector: Healthcare
Industry: Medical Instruments & Supplies

Latest News

Abingdon Health Reports Strong Growth and Expansion in FY25 Results

Abingdon Health PLC ( ($GB:ABDX) ) has provided an announcement. Abingdon Health plc reported significant growth and expansion in its final results...

TipRanks UK Auto-Generated Newsdesk11 days ago

BD’s Earnings Call: Strong Growth Amid Challenges

TipRanks Auto-Generated Newsdesk15 days ago

Abingdon Health PLC Secures Shareholder Approval for Fundraising

TipRanks UK Auto-Generated Newsdesk23 days ago

BCAL Diagnostics Schedules Annual General Meeting for November 2025

TipRanks Australian Auto-Generated Newsdesk25 days ago

BCAL Diagnostics Schedules Annual General Meeting for 2025

TipRanks Australian Auto-Generated Newsdesk25 days ago
ABCD
1SymbolPriceChangeVol
2BDX$192.69+1.6%1.76M
3
4
5
6

Get Becton Dickinson and Company Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.